Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose radiotherapy plus chemoimmunotherapy as neoadjuvant treatment for resectable esophageal squamous cell carcinoma
ChiCTR2500113560Phase 2Not yet recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Dec 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, carboplatin and PD-1 Monoclonal Antibody in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Army Specialized Medical Center. Primary endpoint: Pathological Complete Response (pCR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
paclitaxelcarboplatinPD-1 Monoclonal Antibody
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500113560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113560.